{
  "pmcid": "2564857",
  "sha256": "9b29432deead9f733acc9bce035e899620f0eb47c65b04ce930dbce62a0f1a39",
  "timestamp_utc": "2025-11-09T22:33:30.257650+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.508641686182667,
    "reading_ease": 18.90724043715852,
    "word_count": 244
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Doxycycline as an Adjunct to Endovascular Aneurysm Repair"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "patients undergoing EVAR were randomised"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "patients undergoing EVAR were randomised to receive doxycycline (100 mg twice daily) or placebo for 6 months"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the effect of doxycycline, an MMP inhibitor, on EVAR outcomes."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was plasma MMP-9 levels at 6 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using [randomisation method] with allocation concealment via [allocation concealment method]."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Forty-four patients were randomised: 20 to doxycycline and 24 to placebo."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Intention-to-treat analysis showed a significant decrease in plasma MMP-9"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Intention-to-treat analysis showed a significant decrease in plasma MMP-9 in the doxycycline group at 6 months (−16.4±20.7%, P<0.05) compared to a non-significant increase in the placebo group (128.1±73.5%)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [source of funding]."
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}